ImprimisRx announced its participation at the upcoming 2018 American Academy of Ophthalmology (AAO) annual meeting to be held at the McCormick Place Convention Center in Chicago, October 26-30. 

At the conference, attendees will have the opportunity to meet with ImprimisRx representatives in Booth #4254 to learn about Imprimis’s full portfolio of formulations, including a new tropicamide and phenylephrine combination topical offering from its FDA-registered 503B outsourcing facility. This formulation further expands the company’s office-use portfolio of ophthalmic focused compounded medications.

Maggie Jeffries, MD, a board-certified anesthesiologist, will be presenting a poster on Sunday October 28 at 12:45 pm at the conference. The poster titled “Conscious sedation efficacy of the novel medication, MKO Melt, during cataract surgery” will summarize the results of her investigator led 611-patient IRB approved prospective, controlled, randomized, three arm comparator study. The purpose of the study was to compare the conscious sedation efficacy of a non-opioid sublingual troche, Imprimis’s MKO Melt, to diazepam and a diazepam/tramadol/ondansetron combination during cataract surgery.

The MKO Melt (midazolam/ketamine/ondansetron) is a noninvasive, non-opioid, patented, sublingual troche used typically by physicians for short term procedures, with potentially 100 million addressable procedures in the U.S. annually across multiple verticals and a potential multi-billion-dollar opportunity. Imprimis Pharmaceuticals recently formed a new subsidiary, Melt Pharmaceuticals, which is pursuing the development of 505(b)(2) drug candidates for FDA approval based on the underlying technology of the MKO Melt.